iGenetic Diagnostics launches liquid biopsy test LiquidHALLMARK in India

iGenetic partners with Singapore-headquartered Lucence Diagnostics to make its liquid biopsy test LiquidHALLMARK available in India. The blood test spans multiple cancer-causing mutations and viruses to improve cancer diagnosis and treatment selection for patients with advanced cancer


New Delhi: The leading Indian pathology chain, iGenetic Diagnostics, has entered into a strategic collaboration with Lucence Diagnostics, a genomic medicine company headquartered in Singapore, to make its liquid biopsy tests for early cancer detection and treatment available in India.

Through this collaboration, iGenetic Diagnostics will be making Lucence’s liquid biopsy test – LiquidHALLMARK available to the Indian masses. The test is the world’s first blood test to span multiple cancer-causing mutations and viruses. This test improves cancer diagnosis and treatment selection for patients with advanced cancer. The blood test analyzes the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.

“Delivering advanced molecular diagnostics that can enable a quick and precise diagnosis will help to save lives. We are excited to collaborate with Lucence to deliver their proprietary liquid biopsy tests for early cancer detection and better treatment selection to patients in India. Lucence’s technology will help doctors personalize treatment for their patients and improve patient outcomes,’’ said Arunima Patel, CEO and Managing Director, iGenetic Diagnostics.

iGenetic specialises in providing the full spectrum of pathology solutions including molecular diagnostic services that deliver quicker and accurate results for its customers. The company is headquartered in Mumbai with seven processing labs and over 20 collection centres across India. The new blood test will further strengthen iGenetic Diagnostics’ offerings in India.

LiquidHALLMARK targets a wide range of cancers, especially the cancer types that are most prevalent in Asia, like lung, colon and breast cancers. The turnaround time for this test is also shorter with results coming back in days instead of over a week for current approaches. The test is based on Lucence’s molecular watermarking technology AmpliMARK™with sensitivity and specificity of up to 99.9%, which is supported by its AI-powered clinical analytics engine SunTzu.AI.

“Lucence is delighted to collaborate with iGenetic to launch our liquid biopsy tests in India. We are focused on reducing avoidable cancer deaths, particularly in Asia, where more than 4 million cancer deaths occur annually. With iGenetic’s experience and presence in India, we are confident that this partnership will drive better cancer care in the country,” said Dr Min-Han Tan, Founder and CEO, Lucence Diagnostics.